Chicago, Il., June 5, 2007 -- Researchers at the University of Southern California (USC) have identified specific molecular markers that may help to predict tumor recurrence in stage II and III colon cancer patients.The findings may also help identify stage II colon cancer patients who are more likely to benefit from adjuvant chemotherapy following surgery, says Georg Lurje M.D., research associate at the Keck School of Medicine of the University of Southern California (USC).
